ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

HIK Hikma Pharmaceuticals Plc

1,854.00
41.00 (2.26%)
25 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Hikma Pharmaceuticals Plc LSE:HIK London Ordinary Share GB00B0LCW083 ORD SHS 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  41.00 2.26% 1,854.00 1,839.00 1,841.00 1,882.00 1,750.00 1,750.00 760,985 16:35:14
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 2.88B 192M 0.8685 21.19 4.07B
Hikma Pharmaceuticals Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker HIK. The last closing price for Hikma Pharmaceuticals was 1,813p. Over the last year, Hikma Pharmaceuticals shares have traded in a share price range of 1,711.00p to 2,222.00p.

Hikma Pharmaceuticals currently has 221,081,676 shares in issue. The market capitalisation of Hikma Pharmaceuticals is £4.07 billion. Hikma Pharmaceuticals has a price to earnings ratio (PE ratio) of 21.19.

Hikma Pharmaceuticals Share Discussion Threads

Showing 176 to 199 of 1875 messages
Chat Pages: Latest  15  14  13  12  11  10  9  8  7  6  5  4  Older
DateSubjectAuthorDiscuss
01/10/2014
07:33
Yep, just seen it.

Hikma Pharmaceuticals has received approval of its new drug application for colchicine 0.6mg capsules by the US Food and Drug Administration. Hikma will market its colchicine under the brand name MITIGARE. MITIGARE is indicated for prophylaxis of gout flares in adults. This NDA has been approved under section 505(b)(2) of the US Federal Food Drug and Cosmetic Act. Hikma chairman and chief executive Said Darwazah said: "This approval demonstrates our strong regulatory capabilities and the successful execution of our strategy to develop a more differentiated product portfolio for the US market

broadwood
30/9/2014
18:16
FDA APPROVAL FOR COLCHICINE
mirabeau
30/9/2014
17:02
No new broker recs so its a mystery.
Not complaining.

broadwood
30/9/2014
16:00
Someone knows something, nice rise today
coppertrader
30/9/2014
12:21
not any I am aware of.
r ball
30/9/2014
11:37
Going nicely today. Special factors?
broadwood
29/9/2014
09:15
HIKMA Pharmaceuticals, which manufactures generic pharmaceutical products, is reportedly looking at buying US-based rival CorePharma for up to $1bn (£615m).
broadwood
19/9/2014
04:46
Turbulence. Ignore
r ball
18/9/2014
00:20
Does anyone know why this is sinking after it has just released an update with a 45% rise in profits? Is it this scottish debarcle or more to do with the reduction in their labeled drugs?
coppertrader
04/9/2014
17:45
Good article, thanks cla
coppertrader
21/8/2014
16:46
Normal service resumed.
broadwood
20/8/2014
23:20
Looking like it's an over-reaction to pressure on branded sales due to middle-east turmoil. The overall results remain fantastic and regardless of ME, this is still a massively profitable business with great growth prospects. I imagine the drop will be be seen as a buying opportunity tomorrow.
stdyeddy
20/8/2014
13:46
What happened at 11am? Results call? Price was down 20p til then and suddenly it nose-dived....
adamb1978
20/8/2014
13:41
Did I miss something? Was this really a profit warning? Branded is forecast down but overall the business is massively up.
stdyeddy
20/8/2014
13:36
Well there you have it; the market has spoken. Evidently +44% is rubbish. What a terrible set of numbers! Why can't Hikma make 10% like everyone else and whine about currency headwinds? Am really not surprised that the stock is down 8%. I certainly hope they don't manage a 100% profit increase next time because I'll probably be wiped out!
stdyeddy
20/8/2014
10:21
Even annualising the interm EPS with no growth, gets you to EPS of about 106p based on FX rate of 1.65, so a PE of just under 16x.

For a fast growing mid cap with an unlevered balance sheet and operating in a sector which is rife with M&A activity at the moment, that strikes me as very cheap. Am sturggling to understand why Mr Market doesnt like the results today

adamb1978
20/8/2014
10:21
Even annualising the interm EPS with no growth, gets you to EPS of about 106p based on FX rate of 1.65, so a PE of just under 16x.

For a fast growing mid cap with an unlevered balance sheet and operating in a sector which is rife with M&A activity at the moment, that strikes me as very cheap. Am sturggling to understand why Mr Market doesnt like the results today

adamb1978
20/8/2014
10:16
COnsensus forecasts of 73p EPS for this year need a massive upgrade surely?!? Am I missing something?
adamb1978
20/8/2014
08:23
results already in the price. might take a while to digest.
r ball
20/8/2014
08:19
Plus a special dividend! Not good? What was everyone hoping for?
stdyeddy
20/8/2014
08:08
These are great figures: profits up 44%. How come the market isn't reacting positively?
stdyeddy
20/8/2014
07:36
Todays results may get us in. I think an share price of 2000p should do it (around 14% increase from here).
painter
15/8/2014
12:27
The timing is perfect for great results to come out when we are already at an all time high. The way this is going, we will be on the ftse 100 by christmas.
coppertrader
25/7/2014
19:41
Hikma reaching all time highs
mrblonde77
Chat Pages: Latest  15  14  13  12  11  10  9  8  7  6  5  4  Older

Your Recent History

Delayed Upgrade Clock